Recently, Antonia et al . (1) have published a phase III randomized trial exploring durvalumab after concurrent chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC). Click to show full abstract
Recently, Antonia et al . (1) have published a phase III randomized trial exploring durvalumab after concurrent chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC).
               
Click one of the above tabs to view related content.